title: Falls and Frailty in Prostate Cancer Survivors: Current, Past, and Never Users of Androgen Deprivation Therapy.
abstract: OBJECTIVE
  To compare the prevalence of and association between falls and frailty of prostate cancer survivors (PCSs) who were current, past or never users of androgen deprivation therapy (ADT).
  
  
  METHODS
  Cross-sectional.
  
  
  METHODS
  Mail and electronic survey.
  
  
  METHODS
  PCSs (N = 280; mean age 72 ± 8).
  
  
  METHODS
  Cancer history, falls, and frailty status (robust, prefrail, frail) using traditionally defined and obese phenotypes.
  
  
  RESULTS
  Current (37%) or past (34%) ADT users were more than twice as likely to have fallen in the previous year as never users (15%) (P = .002). ADT users had twice as many recurrent falls (P < .001) and more fall-related injuries than unexposed men (P = .01). Current (43%) or past (40%) ADT users were more likely to be classified as prefrail or frail than never users (15%) (P < .001), and the prevalence of combined obese frailty + prefrailty was even greater in current (59%) or past (62%) ADT users than never users (25%) (P < .001). Traditional and obese frailty significantly increased the likelihood of reporting falls in the previous year (odds ratio (OR) = 2.15, 95% CI = 1.18-3.94 and OR = 2.97, 95% CI = 1.62-5.58, respectively) and was also associated with greater risk of recurrent falls (OR = 3.10, 95% CI = 1.48-6.5 and OR = 3.99, 95% CI = 1.79-8.89, respectively).
  
  
  CONCLUSIONS
  Current and past exposure to ADT is linked to higher risk of falls and frailty than no treatment. PCSs should be appropriately counseled on fall prevention strategies, and approaches to reduce frailty should be considered.
authors.affiliation: Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.|School of Nursing, Oregon Health & Science University, Portland, Oregon.
authors.forename: Kerri M
authors.initials: KM
authors.lastname: Winters-Stone
authors.affiliation: Department of Medicine, Oregon Health & Science University, Portland, Oregon.
authors.forename: Esther
authors.initials: E
authors.lastname: Moe
authors.affiliation: Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.
authors.forename: Julie N
authors.initials: JN
authors.lastname: Graff
authors.affiliation: School of Nursing, Oregon Health & Science University, Portland, Oregon.
authors.forename: Nathan F
authors.initials: NF
authors.lastname: Dieckmann
authors.affiliation: School of Nursing, Oregon Health & Science University, Portland, Oregon.
authors.forename: Sydnee
authors.initials: S
authors.lastname: Stoyles
authors.affiliation: School of Nursing, Oregon Health & Science University, Portland, Oregon.
authors.forename: Carolyn
authors.initials: C
authors.lastname: Borsch
authors.affiliation: Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.
authors.forename: Joshi J
authors.initials: JJ
authors.lastname: Alumkal
authors.affiliation: Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.
authors.forename: Christopher L
authors.initials: CL
authors.lastname: Amling
authors.affiliation: Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.
authors.forename: Tomasz M
authors.initials: TM
authors.lastname: Beer
mesh_terms: D000058:Accidental Falls / Q000706:statistics & numerical data*; D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D016330:Frail Elderly / Q000706:statistics & numerical data*; D006801:Humans; D008297:Male; D009765:Obesity / Q000453:epidemiology; D015995:Prevalence; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000453:epidemiology; D012306:Risk; D017741:Survivors
chemical_list: D000726:Androgen Antagonists
keywords: androgens; falls; frailty; prostate cancer; survivorship